Abstract
Discussing carrier screening during preconception consultation in primary care has a number of advantages in terms of promoting autonomy and enabling the greatest range of reproductive choices. For those with a family history of an inherited condition, this ought to be a routine discussion; however, this can be expanded to include the wider population, especially for those conditions for which carrier frequencies are considered relatively common. There is published literature from around the world regarding experiences with carrier screening in primary care for cystic fibrosis, haemoglobinopathies, fragile X syndrome, Tay–Sachs disease and spinal muscular atrophy, although many of these have tended to focus on consultations during rather than before pregnancy. Overall, these studies reveal that population carrier screening is well received by the participants with apparent minimal psychosocial harms; however, challenges exist in terms of approaches to ensure couples receive adequate information to make personally relevant decisions and for ongoing health professional engagement.
Similar content being viewed by others
References
Ahmed S, Green J, Hewison J (2005) Antenatal thalassaemia carrier testing: women's perceptions of “information” and “consent”. J Med Screen 12(2):69–77
Al Arrayed S, Al Hajeri A (2010) Public awareness of sickle cell disease in Bahrain. Ann Saudi Med 30(4):284–288
American College of Obstetricians and Gynecologists (2005) ACOG Committee opinion. Number 325, December 2005. Update on carrier screening for cystic fibrosis. Obstet Gynecol 106(6):1465–1468
American College of Obstetricians and Gynecologists (2009) ACOG Committee opinion no. 432: spinal muscular atrophy. Obstet Gynecol 113(5):1194–1196
American College of Obstetricians and Gynecologists (2011) ACOG Committee opinion no. 486: update on carrier screening for cystic fibrosis. Obstet Gynecol 117(4):1028–1031
Angastiniotis M, Modell B (1998) Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 850:251–269
Angastiniotis M, Modell B, Englezos P, Boulyjenkov V (1995) Prevention and control of haemoglobinopathies. Bull World Health Organ 73(3):375–386
Anido A, Carlson LM, Taft L, Sherman SL (2005) Women's attitudes toward testing for fragile X carrier status: a qualitative analysis. J Genet Couns 14(4):295–306
Anido A, Carlson LM, Sherman SL (2007) Attitudes toward fragile x mutation carrier testing from women identified in a general population survey. J Genet Couns 16(1):97–104
Archibald AD, Jaques AM, Wake S, Collins VR, Cohen J, Metcalfe SA (2009) “It's something I need to consider”: decisions about carrier screening for fragile X syndrome in a population of non-pregnant women. Am J Med Genet A 149A(12):2731–2738
Baars MJ, Henneman L, ten Kate LP (2004) Preconceptional cystic fibrosis carrier screening: opinions of general practitioners, gynecologists, and pediatricians in the Netherlands. Genet Test 8(4):431–436
Basel-Vanagaite L, Taub E, Drasinover V, Magal N, Brudner A, Zlotogora J, Shohat M (2008) Genetic carrier screening for spinal muscular atrophy and spinal muscular atrophy with respiratory distress 1 in an isolated population in Israel. Genet Test 12(1):53–56
Bekker H, Modell M, Denniss G, Silver A, Mathew C, Bobrow M, Marteau T (1993) Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ 306(6892):1584–1586
Bekker H, Denniss G, Modell M, Bobrow M, Marteau T (1994) The impact of population based screening for carriers of cystic fibrosis. J Med Genet 31(5):364–368
Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF (2011) Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 3(65):65ra64
Berkenstadt M, Ries-Levavi L, Cuckle H, Peleg L, Barkai G (2007) Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenat Diagn 27(11):991–994
Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Tambor ES, Holtzman NA (1996) Educating patients about cystic fibrosis carrier screening in a primary care setting. Arch Fam Med 5(6):336–340
Borry P, Henneman L, Lakeman P, ten Kate LP, Cornel MC, Howard HC (2011) Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod 26(5):972–977
Botkin JR, Alemagno S (1992) Carrier screening for cystic fibrosis: a pilot study of the attitudes of pregnant women. Am J Public Health 82(5):723–725
Boulton M, Cummings C, Williamson R (1996) The views of general practitioners on community carrier screening for cystic fibrosis. Br J Gen Pract 46(406):299–301
Cao A, Rosatelli MC, Monni G, Galanello R (2002) Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 29(2):305–328, vi-vii
Chen LS, Goodson P (2007) Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: a theory-guided systematic review. Genet Med 9(7):442–450
Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW 3rd, Phillips JA 3rd (1996) Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet 58(3):617–627
Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB (2010) Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 18(10):1077–1083
Cronister A, DiMaio M, Mahoney MJ, Donnenfeld AE, Hallam S (2005) Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet Med 7(4):246–250
Cuckle H, Quirke P, Sehmi I, Lewis F, Murray J, Cross D, Cuckle P, Ozols B (1996) Antenatal screening for cystic fibrosis. Br J Obstet Gynaecol 103(8):795–799
Decruyenaere M, Evers-Kiebooms G, Denayer L, Van den Berghe H (1992) Cystic fibrosis: community knowledge and attitudes towards carrier screening and prenatal diagnosis. Clin Genet 41(4):189–196
Delatycki MB (2008) Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res Hum Genet 11(4):422–430
Dodge JA, Lewis PA, Stanton M, Wilsher J (2007) Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J 29(3):522–526
Faden RR, Tambor ES, Chase GA, Geller G, Hofman KJ, Holtzman NA (1994) Attitudes of physicians and genetics professionals toward cystic fibrosis carrier screening. Am J Med Genet 50(1):1–11
Fanos JH, Spangner KA, Musci TJ (2006) Attitudes toward prenatal screening and testing for Fragile X. Genet Med 8(2):129–133
Finucane B (1996) Should all pregnant women be offered carrier testing for fragile X syndrome? Clin Obstet Gynecol 39(4):772–782
Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG Jr, Warren ST et al (1991) Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67(6):1047–1058
Gason AA, Sheffield E, Bankier A, Aitken MA, Metcalfe S, Barlow Stewart K, Delatycki MB (2003) Evaluation of a Tay–Sachs disease screening program. Clin Genet 63(5):386–392
Geva E, Yaron Y, Shomrat R, Ben-Yehuda A, Zabari S, Peretz H, Naiman T, Yeger H, Orr-Urtreger A (2000) The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families. Genet Test 4(3):289–292
Godard B, ten Kate L, Evers-Kiebooms G, Ayme S (2003) Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 11(Suppl 2):S49–S87
Gordon C, Walpole I, Zubrick SR, Bower C (2003) Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later. Am J Med Genet 120A(2):199–208
Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ, Subcommittee on Cystic Fibrosis Screening AoGSCAACoMG (2001) Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 3(2):149–154
Gross SJ, Pletcher BA, Monaghan KG, Professional Practice Guidelines Committee (2008) Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 10(1):54–56
Hagerman RJ, Hagerman PJ (2002) Fragile X syndrome: diagnosis, treatment, and research. Johns Hopkins University Press
Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57(1):127–130
Hantash FM, Goos DM, Crossley B, Anderson B, Zhang K, Sun W, Strom CM (2011) FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med 13(1):39–45
Harris HJ, Scotcher D, Craufurd D, Wallace A, Harris R (1992) Cystic fibrosis carrier screening at first diagnosis of pregnancy in general practice. Lancet 339(8808):1539
Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R (1993) Cystic fibrosis carrier testing in early pregnancy by general practitioners. BMJ 306(6892):1580–1583
Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R (1996) Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice. Br J Gen Pract 46(405):225–227
Hartley NE, Scotcher D, Harris H, Williamson P, Wallace A, Craufurd D, Harris R (1997) The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 34(6):459–464
Henneman L, Bramsen I, Van Os TA, Reuling IE, Heyerman HG, van der Laag J, van der Ploeg HM, ten Kate LP (2001a) Attitudes towards reproductive issues and carrier testing among adult patients and parents of children with cystic fibrosis (CF). Prenat Diagn 21(1):1–9
Henneman L, Bramsen I, van der Ploeg HM, Ader HJ, van der Horst HE, Gille JJ, ten Kate LP (2001b) Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet 38(10):695–703
Henneman L, Bramsen I, van der Ploeg HM, ten Kate LP (2002) Preconception cystic fibrosis carrier couple screening: impact, understanding, and satisfaction. Genet Test 6(3):195–202
Henneman L, Bramsen I, van Kempen L, van Acker MB, Pals G, van der Horst HE, Ader HJ, van der Ploeg HM, ten Kate LP (2003) Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. Comm Genet 6(1):5–13
Heredero-Baute L (2004) Community-based program for the diagnosis and prevention of genetic disorders in Cuba. Publ Health Genomics 7(2–3):130–136
Hill MK, Archibald AD, Cohen J, Metcalfe SA (2010) A systematic review of population screening for fragile X syndrome. Genet Med 12(7):396–410
Honnor M, Zubrick SR, Walpole I, Bower C, Goldblatt J (2000) Population screening for cystic fibrosis in Western Australia: community response. Am J Med Genet 93(3):198–204
Huang KF, Chen WY, Tsai YC, Lin CC, Chen SH, Tseng CY, Tzeng CC (2003) Original article pilot screening for fragile X carrier in pregnant women of southern Taiwan. J Chin Med Assoc 66(4):204–209
Human Genetics Society of Australasia (2010) Cystic fibrosis population screening position paper
Ioannou L, Massie J, Collins V, McClaren B, Delatycki MB (2010) Population-based genetic screening for cystic fibrosis: attitudes and outcomes. Publ Health Genomics 13(7–8):449–456
Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, Greco C, Des Portes V, Jardini T, Levine R, Berry-Kravis E, Brown WT, Schaeffer S, Kissel J, Tassone F, Hagerman PJ (2003) Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 72(4):869–878
Kaback MM (2001) Screening and prevention in Tay–Sachs disease: origins, update, and impact. Adv Genet 44:253–265
Kallinen J, Marin K, Heinonen S, Mannermaa A, Palotie A, Ryynanen M (2001) Wide scope prenatal diagnosis at Kuopio University Hospital 1997–1998: integration of gene tests and fetal karyotyping. BJOG 108(5):505–509
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922):1073–1080
Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, ten Kate LP (2009) Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation? Eur J Hum Genet 17(8):999–1009
Levenkron JC, Loader S, Rowley PT (1997) Carrier screening for cystic fibrosis: test acceptance and one year follow-up. Am J Med Genet 73(4):378–386
Lévesque S, Dombrowski C, Morel ML, Rehel R, Côté JS, Bussières J, Morgan K, Rousseau F (2009) Screening and instability of FMR1 alleles in a prospective sample of 24,449 mother–newborn pairs from the general population. Clin Genet 76(6):511–523
Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr, Rowley PT (1996) Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 59(1):234–247
Locock L, Kai J (2008) Parents' experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era. Br J Gen Pract 58(548):161–168
Massie J, Petrou V, Forbes R, Curnow L, Ioannou L, Du Sart D, Bankier A, Delatycki M (2009) Population-based carrier screening for cystic fibrosis in Victoria: the first three years experience. Aust N Z J Obstet Gynaecol 49(5):484–489
Maxwell SJ, Kyne G, Molster C, Barker NM, Ormsby J, O'Leary P (2011) Perceptions of population cystic fibrosis prenatal and preconception carrier screening among individuals with cystic fibrosis and their family members. Genet Test Mol Biomarkers 15(3):159–164
McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M (2008) ‘It is not in my world’: an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 16(4):435–444
McClaren BJ, Metcalfe S, Aitken M, Massie J, Ukoumunne OC, Amor DJ (2010) Uptake of cystic fibrosis carrier testing in families after diagnosis through newborn screening. Eur J Hum Genet 18(10):1084–1089
McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ (2005) Genetic counseling for fragile X syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 14(4):249–270
McConkie-Rosell A, Abrams L, Finucane B, Cronister A, Gane LW, Coffey SM, Sherman S, Nelson LM, Berry-Kravis E, Hessl D, Chiu S, Street N, Vatave A, Hagerman RJ (2007) Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Couns 16(5):593–606
Meadows KL, Sherman SL (1996) Fragile X syndrome: examination of issues pertaining to population-based screening. Screening 4:175–192
Melancon MJ, De Braekeleer M (1996) Adolescents' attitude towards carrier testing for cystic fibrosis. Eur J Hum Genet 4(6):305–306
Mennie M, Campbell H, Liston WA, Brock DJ (1998) Attitudes of general practitioners to screening for cystic fibrosis. J Med Screen 5(1):11–15
Metcalfe S, Hurworth R, Newstead J, Robins R (2002) Needs assessment study of genetics education for general practitioners in Australia. Genet Med 4(2):71–77
Metcalfe S, Jacques A, Archibald A, Burgess T, Collins V, Henry A, McNamee K, Sheffield L, Slater H, Wake S, Cohen J (2008) A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genet Med 10(7):525–535
Mitchell JJ, Capua A, Clow C, Scriver CR (1996) Twenty-year outcome analysis of genetic screening programs for Tay–Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 59(4):793–798
Modell M (1993) Screening for carriers of cystic fibrosis—a general practitioner's perspective. BMJ 307(6908):849–852
Modell M, Wonke B, Anionwu E, Khan M, Tai SS, Lloyd M, Modell B (1998) A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders. BMJ 317(7161):788–791
Muralidharan K, Wilson RB, Ogino S, Nagan N, Curtis C, Schrijver I (2011) Population carrier screening for spinal muscular atrophy a position statement of the association for molecular pathology. J Mol Diagn 13(1):3–6
Musci TJ (2005) Screening for single gene genetic disease. Gynecol Obstet Invest 60(1):19–26
Musci TJ, Caughey AB (2005) Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 192(6):1905–1912
Myers MF, Bernhardt BA, Tambor ES, Holtzman NA (1994) Involving consumers in the development of an educational program for cystic fibrosis carrier screening. Am J Hum Genet 54(4):719–726
NHS. Thalassaemia and Sickle Cell Screening Programme. Accessed July 2011, from http://sct.screening.nhs.uk/index.php
Nolin SL, Lewis FA 3rd, Ye LL, Houck GE Jr, Glicksman AE, Limprasert P, Li SY, Zhong N, Ashley AE, Feingold E, Sherman SL, Brown WT (1996) Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 59(6):1252–1261
Nolin SL, Brown WT, Glicksman A, Houck GE Jr, Gargano AD, Sullivan A, Biancalana V, Brondum-Nielsen K, Hjalgrim H, Holinski-Feder E, Kooy F, Longshore J, Macpherson J, Mandel JL, Matthijs G, Rousseau F, Steinbach P, Vaisanen ML, von Koskull H, Sherman SL (2003) Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 72(2):454–464
Ormond KE, Iris M, Banuvar S, Minogue J, Annas GJ, Elias S (2007) What do patients prefer: informed consent models for genetic carrier testing. J Genet Couns 16(4):539–550
O'Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373(9678):1891–1904
Otsuka S, Sakamoto Y, Siomi H, Itakura M, Yamamoto K, Matumoto H, Sasaki T, Kato N, Nanba E (2010) Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain Dev 32(2):110–114
Palomaki GE (1994) Population based prenatal screening for the fragile X syndrome. J Med Screen 1(1):65–72
Payne Y, Williams M, Cheadle J, Stott NC, Rowlands M, Shickle D, West G, Meredith L, Goodchild M, Harper PS, Clarke A (1997) Carrier screening for cystic fibrosis in primary care: evaluation of a project in South Wales. The South Wales Cystic Fibrosis Carrier Screening Research Team. Clin Genet 51(3):153–163
Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, Barkai G (2000) Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 20(8):611–614
Poppelaars FA, van der Wal G, Braspenning JC, Cornel MC, Henneman L, Langendam MW, ten Kate LP (2003a) Possibilities and barriers in the implementation of a preconceptional screening programme for cystic fibrosis carriers: a focus group study. Public Health 117(6):396–403
Poppelaars FA, Henneman L, Ader HJ, Cornel MC, Hermens RP, Van Der Wal G, Ten Kate LP (2003b) How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population. Comm Genet 6(3):157–165
Poppelaars FA, Henneman L, Ader HJ, Cornel MC, Hermens RP, van der Wal G, ten Kate LP (2004a) Preconceptional cystic fibrosis carrier screening: attitudes and intentions of the target population. Genet Test 8(2):80–89
Poppelaars FA, Ader HJ, Cornel MC, Henneman L, Hermens RP, van der Wal G, ten Kate LP (2004b) Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening. J Genet Couns 13(1):31–44
Prior TW (2010) Spinal muscular atrophy: a time for screening. Curr Opin Pediatr 22(6):696–702
Prior TW, Professional Practice Guidelines Committee (2008) Carrier screening for spinal muscular atrophy. Genet Med 10(11):840–842
Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, Conlan T, Schmalz B, Montgomery L, Ziegler K, Noonan C, Hashimoto S, Garner S (2010) Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 152A(7):1608–1616
Qureshi N, Armstrong S, Modell B (2006) GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. Fam Pract 23(1):106–110
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066–1073
Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N et al (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245(4922):1059–1065
Ryynanen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K (1999) Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 7(2):212–216
Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R (2010) Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat 31(11):1240–1250
Sherman S, Pletcher BA, Driscoll DA (2005) Fragile X syndrome: diagnostic and carrier testing. Genet Med 7(8):584–587
Snow K, Doud LK, Hagerman R, Pergolizzi RG, Erster SH, Thibodeau SN (1993) Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet 53(6):1217–1228
Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A (2003) Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 7(16):1–106
Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, Castellani C (2007) A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6(1):57–65
Southern KW, Merelle MM, Dankert-Roelse JE, Nagelkerke AD (2009) Newborn screening for cystic fibrosis. Cochrane Database Syst Rev (1): CD001402. doi:10.1002/14651858.CD001402.pub2
Spence WC, Black SH, Fallon L, Maddalena A, Cummings E, Menapace-Drew G, Bick DP, Levinson G, Schulman JD, Howard-Peebles PN (1996) Molecular fragile X screening in normal populations. Am J Med Genet 64(1):181–183
Srinivasan BS, Evans EA, Flannick J, Patterson AS, Chang CC, Pham T, Young S, Kaushal A, Lee J, Jacobson JL, Patrizio P (2010) A universal carrier test for the long tail of Mendelian disease. Reprod Biomed online 21(4):537–551
Strom CM, Crossley B, Buller-Buerkle A, Jarvis M, Quan F, Peng M, Muralidharan K, Pratt V, Redman JB, Sun W (2011) Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis. Genet Med 13(2):166–172
Su YN, Hung CC, Lin SY, Chen FY, Chern JP, Tsai C, Chang TS, Yang CC, Li H, Ho HN, Lee CN (2011) Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005–2009: a prospective population-based cohort study. PLoS One 6(2):e17067
Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Holtzman NA (1994) Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 55(4):626–637
Toledano-Alhadef H, Basel-Vanagaite L, Magal N, Davidov B, Ehrlich S, Drasinover V, Taub E, Halpern GJ, Ginott N, Shohat M (2001) Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 69(2):351–360
Watson EK, Williamson R, Chapple J (1991a) Attitudes to carrier screening for cystic fibrosis: a survey of health care professionals, relatives of sufferers and other members of the public. Br J Gen Pract 41(347):237–240
Watson EK, Mayall E, Chapple J, Dalziel M, Harrington K, Williams C, Williamson R (1991b) Screening for carriers of cystic fibrosis through primary health care services. BMJ 303(6801):504–507
Weinreich SS, de Lange-de Klerk ES, Rijmen F, Cornel MC, de Kinderen M, Plass AM (2009) Raising awareness of carrier testing for hereditary haemoglobinopathies in high-risk ethnic groups in the Netherlands: a pilot study among the general public and primary care providers. BMC Public Health 9:338
Welkenhuysen M, Evers-Kiebooms G, Decruyenaere M, Van den Berghe H, Bande-Knops J, Van Gerven V (1996) Adolescents' attitude towards carrier testing for cystic fibrosis and its relative stability over time. Eur J Hum Genet 4(1):52–62
WHO (2006) Thalassaemia and other haemoglobinopathies: report by the Secretariat
Wildhagen MF, van Os TA, Polder JJ, ten Kate LP, Habbema JD (1998) Explorative study of costs, effects and savings of screening for female fragile X premutation and full mutation carriers in the general population. Comm Genet 1(1):36–47
Wilfond BS, Fost N (1990) The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA 263(10):2777–2783
Williamson R (1993) Universal community carrier screening for cystic fibrosis? Nat Genet 3(3):195–201
Wong L, George E, Tan J-A (2011a) A holistic approach to education programs in thalassemia for a multi-ethnic population: consideration of perspectives, attitudes, and perceived needs. J Comm Genet 2(2):71–79
Wong LP, George E, Tan JA (2011b) Public perceptions and attitudes toward thalassaemia: influencing factors in a multi-racial population. BMC Public Health 11:193
Zlotogora J, Carmi R, Lev B, Shalev SA (2009) A targeted population carrier screening program for severe and frequent genetic diseases in Israel. Eur J Hum Genet 17(5):591–597
Acknowledgements
The author is grateful to Dr. Belinda McClaren, Dr. Alison Archibald, and Nicole Cousens for help with specific literature, and Loren Plunkett and Mark Adams for administrative support. This work was supported by the Victorian Government's Operational Infrastructure Support Program.
Declaration
The author of this paper declares that she has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Special Issue: Genetic Aspects of Preconception Consultation in Primary Care
Rights and permissions
About this article
Cite this article
Metcalfe, S.A. Carrier screening in preconception consultation in primary care. J Community Genet 3, 193–203 (2012). https://doi.org/10.1007/s12687-011-0071-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12687-011-0071-z